Kyverna Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kyverna Therapeutics (KYTX).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingOverweight# Analysts6Avg. Consensus PT$22Upside to Avg. PT+250.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
May 15, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$20→$25
May 13, 2026	JP Morgan	Brian Cheng	PT Cut	Overweight	$30→$29
Apr 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$20
Dec 16, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$31→$33
Dec 4, 2025	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$20→$25
Oct 30, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$27→$31
Oct 27, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$10→$20
Oct 8, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$24→$27
Aug 29, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$5→$10
Aug 20, 2025	William Blair	Sami Corwin	Initiate	Outperform	—
May 27, 2025	HC Wainwright & Co.	Mitchell Kapoor	Upgrade	Neutral→Buy	$4→$5
Apr 3, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$6→$4
Apr 1, 2025	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$40→$20
Nov 20, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$7→$6
Nov 15, 2024	Wells Fargo	Derek Archila	PT Cut	Overweight	$44→$24
Oct 10, 2024	UBS	Trung Huynh	Initiate	Buy	$13
Sep 19, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$7
Aug 15, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$8→$7
Jul 31, 2024	JP Morgan	Brian Cheng	PT Cut	Overweight	$39→$33

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the price target from $20 to $25.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $31 to $33.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

Morgan Stanley analyst Michael Ulz maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $20 to $25.

Benzinga Newsdesk

Kyverna Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Kyverna Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

People Also Watch

People Also Watch

Kyverna Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Kyverna Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PROHC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PROJP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PROHC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PROWells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PROMorgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25